The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein

Biochemical and Biophysical Research Communications

Volumn 300, Issue 2, 2003, Pages 501-506

  Sangvanich, Polkit ^a   Mackness, Bharti ^a   Gaskell, Simon J ^a   Durrington, Paul ^a   Mackness, Michael ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

High density lipoprotein; Low density lipoprotein; Mass spectrometry; Oxidation; Paraoxonase

Indexed keywords

ANGIOTENSIN; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; COPPER; HIGH DENSITY LIPOPROTEIN; HISTIDINE; LOW DENSITY LIPOPROTEIN; 4 HYDROXYNONENAL; 4-HYDROXY-2-NONENAL; ALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ARTICLE; COVALENT BOND; ELECTROSPRAY MASS SPECTROMETRY; INCUBATION TIME; LIPID PEROXIDATION; LIPID STORAGE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LIPID INTERACTION; PROTEIN MODIFICATION; STANDARDIZATION; CHEMISTRY; COMPARATIVE STUDY; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION;

AVES;

ALDEHYDES; HISTIDINE; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 0037427492     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02849-8     Document Type: Article

References (36)

1. Ross R. The pathogenesis of atherosclerosis - an update. N. Engl. J. Med. 314:1986;488-500.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 362:1993;801-809.
3. Esterbauer H., Gebicki J., Puhl H., Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Biol. Med. 13:1992;341-390.
4. Haberland M.E., Fless G.M., Scanu A.M., Fogelman A.M. Malondialdehyde modification of lipoprotein (a) produces avid uptake by human monocyte-macrophages. J. Biol. Chem. 267:1992;4143-4151.
5. Palinski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., Witztum J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1989;1372-1376.
6. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L. Apo E-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14:1994;605-616.
7. Chisholm G.M., Penn M.S. Oxidised lipoproteins and atherosclerosis. Fuster V., Ross R., Topol E.J. Atherosclerosis and Coronary Artery Disease. 1996;129-149 Lippincott-Raven, Philadelphia.
8. Goldstein J.L., Brown M.S. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46:1977;897-927.
9. Steinbrecher U.P., Lougheed M., Kwan W.-C., Dirks M. Recognition of oxidised low density lipoprotein by the scavenger receptor of macrophages results from derivatisation of apolipoprotein B by products of fatty acid peroxidation. J. Biol. Chem. 264:1989;15216-15223.
10. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
11. Esterbauer H., Zollner H., Schaur R.J. Membrane Lipid Oxidation. 1990;CRC Press, Boca Raton.
12. Steinbrecher U.P. Oxidation of human low density lipoprotein results in derivatisation of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262:1989;3603-3608.
13. Uchida K., Stadtman E.R. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-reaction. J. Biol. Chem. 268:1993;6388-6393.
14. Jürgens G., Lang J., Esterbauer H. Modification of human low-density lipoprotein by the lipid peroxidation product 4-hydroxynonenal. Biochim. Biophys. Acta. 875:1986;103-114.
15. Bolgar M.S., Gaskell S.J. Tandem mass spectrometric characterization of modified peptides and proteins. Anal. Chem. 68:1996;2325-2330.
16. M.S. Bolgar, Mass Spectrometric Characterization of Lipid/Protein Conjugates. Dept. of Chemistry, UMIST (1996).
17. Bolgar M.S., Yang C.Y., Gaskell S.J. First direct evidence for lipid/protein conjugation in oxidised human low density lipoprotein. J. Biol. Chem. 271:1996;27999-28001.
18. Blatter M.-C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-85: identity of K-85 with paraoxonase. Eur. J. Biochem. 211:1993;871-879.
19. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:1991;152-154.
20. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129-135.
21. Mackness M.I., Durrington P.N. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
22. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Fault K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase - inhibition of the biological activity of minimally oxidised low-density lipoprotein. J. Clin. Invest. 96:1995;2882-2891.
23. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffmann A., Billicke S., Draganov D., Rosenblat M. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 101:2000;2510-2517.
24. Mackness B., Durrington P.N., Mackness M.I. Lack of protection against oxidative modification of LDL by avian HDL. Biochem. Biophys. Res. Commun. 247:1998;443-446.
25. Shih D.M., Gu L., Xia Y.-R., Navab M., Li W.-F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M.et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.
26. Mackness M.I., Mackness B., Durrington P.N., Fogelman A.M., Berliner J., Lusis A.J., Navab M., Shih D., Fonarow G.C. Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9:1998;319-324.
27. Mackness M.I., Durrington P.N. Lipoprotein analysis for clinical studies. Converse C.A., Skinner E.R. Lipoprotein Analysis: A Practical Approach. 1992;1-42 IRL Press, Oxford, UK.
28. Mackness M.I., Abbott C.A., Arrol S., Durrington P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 294:1993;829-835.
29. Greilberger J., Jürgens G. Oxidation of high-density lipoprotein HDL3 leads to exposure of apo AI and apo AII epitopes and to formation of aldehyde protein adducts and influences building of oxidised low-density lipoprotein to type I and type III collagen in vitro. Biochem. J. 331:1998;185-191.
30. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:2001;473-480.
31. Tew D.G., Southan C., Rice S.Q., Lawrence M.P., Li H., Boyd H.F., Moores K., Gloger I.S., Macphee C.H. Purification, properties, sequencing, and cloning of a lipoprotein-associated serin dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 16:1996;591-599.
32. Rodrigo L., Mackness B., Durrington P.N., Hernandez A., Mackness M.I. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354:2001;1-17.
33. Packard C.J., O'Reilly D.S.J., Caslake M.J., McMahon A.D., Ford I., Cooney J.et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N. Engl. J. Med. 343:2000;1148-1155.
34. Mackness M.I. 'A'-Esterases - enzymes looking for a role? Biochem. Pharmacol. 38:1989;385-390.
35. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., La Du B.N. Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective active of human paraoxonase alloenzymes Q and R. Arterioscler. Thromb. Vasc. Biol. 10:1998;1617-1624.
36. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.S., La Du B.N. Rabbit serum paraoxonase-3 (PON3) is a high-density lipoprotein associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275:2000;33435-33442.